The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

vanilalanine     2-amino-3-(4-hydroxy-3- methoxy...

Synonyms: AGN-PC-00LGCA, SureCN180103, AG-F-49841, HMDB01434, ANW-45964, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of L-3-Methoxytyrosine


High impact information on L-3-Methoxytyrosine


Chemical compound and disease context of L-3-Methoxytyrosine


Biological context of L-3-Methoxytyrosine


Anatomical context of L-3-Methoxytyrosine


Associations of L-3-Methoxytyrosine with other chemical compounds


Gene context of L-3-Methoxytyrosine


Analytical, diagnostic and therapeutic context of L-3-Methoxytyrosine


  1. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Olanow, C.W., Gauger, L.L., Cedarbaum, J.M. Ann. Neurol. (1991) [Pubmed]
  2. 3-O-methyldopa and motor fluctuations in Parkinson's disease. Fabbrini, G., Juncos, J.L., Mouradian, M.M., Serrati, C., Chase, T.N. Neurology (1987) [Pubmed]
  3. Demonstration of 3-methoxytyrosine in the urine of melanoma patients. Agrup, G., Bengtsson, M., Falck, B., Persson, K., Rorsman, H., Rosengren, A.M., Rosengren, E. Acta Derm. Venereol. (1976) [Pubmed]
  4. Catechol-O-methyltransferase decreases levodopa toxicity in vitro. Offen, D., Panet, H., Galili-Mosberg, R., Melamed, E. Clinical neuropharmacology. (2001) [Pubmed]
  5. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Guttman, M., Léger, G., Cedarbaum, J.M., Reches, A., Woodward, W., Evans, A., Diksic, M., Gjedde, A. Ann. Neurol. (1992) [Pubmed]
  6. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Reches, A., Fahn, S. Ann. Neurol. (1982) [Pubmed]
  7. Issues important for rational COMT inhibition. Dingemanse, J. Neurology (2000) [Pubmed]
  8. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Trocóniz, I.F., Naukkarinen, T.H., Ruottinen, H.M., Rinne, U.K., Gordin, A., Karlsson, M.O. Clin. Pharmacol. Ther. (1998) [Pubmed]
  9. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Schuh, L.A., Bennett, J.P. Neurology (1993) [Pubmed]
  10. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Tohgi, H., Abe, T., Kikuchi, T., Takahashi, S., Nozaki, Y. Neurosci. Lett. (1991) [Pubmed]
  11. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. Müller, T., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., Goetze, O., Woitalla, D. Journal of neural transmission (Vienna, Austria : 1996) (2006) [Pubmed]
  12. The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease. Roos, R.A., Tijssen, M.A., van der Velde, E.A., Breimer, D.D. Clinical neurology and neurosurgery. (1993) [Pubmed]
  13. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Kaakkola, S. Drugs (2000) [Pubmed]
  14. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Crevoisier, C., Zerr, P., Calvi-Gries, F., Nilsen, T. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V. (2003) [Pubmed]
  15. Continuous oral administration of L-dihydroxyphenylalanine (L-DOPA) solution to patients with advanced Parkinson's disease. Bennett, J.P., Turk, M., Landow, E. Clinical neuropharmacology. (1989) [Pubmed]
  16. Circadian phase dependent pharmacokinetics of L-dopa, its main metabolites (3-OMD, HVA, DOPAC) and carbidopa in rats. Andre, M.H., Grignon, S., Bruguerolle, B. Fundamental & clinical pharmacology. (1996) [Pubmed]
  17. In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. Deleu, D., Sarre, S., Ebinger, G., Michotte, Y. Naunyn Schmiedebergs Arch. Pharmacol. (1991) [Pubmed]
  18. Proceedings: Significance of 3-methoxytyrosine and its metabolites in urine of patients with sympathetic nervous system tumours. Penchansky, L., Landing, B.H., Shaw, K.N., Taylor, D.J. Arch. Dis. Child. (1975) [Pubmed]
  19. Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Benetello, P., Furlanut, M., Fortunato, M., Pea, F., Baraldo, M. Pharmacol. Res. (1997) [Pubmed]
  20. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice. Törnwall, M., Tuomainen, P., Männistö, P.T. Archives internationales de pharmacodynamie et de thérapie. (1992) [Pubmed]
  21. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Hyland, K., Surtees, R.A., Rodeck, C., Clayton, P.T. Neurology (1992) [Pubmed]
  22. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. Lloyd, K.G., Davidson, L., Hornykiewicz, O. J. Pharmacol. Exp. Ther. (1975) [Pubmed]
  23. Sympathectomy does not modify the levels of dopa or dopamine in the rat dorsal root ganglion. Bertrand, A., Weil-Fugazza, J. Brain Res. (1995) [Pubmed]
  24. Influence of L-3-methoxytyrosine on monoamine synthesis in rat brain. Kehr, W. Naunyn Schmiedebergs Arch. Pharmacol. (1975) [Pubmed]
  25. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. Wenning, G.K., O'Connell, M.T., Patsalos, P.N., Quinn, N.P. Mov. Disord. (1995) [Pubmed]
  26. COMT inhibition in the treatment of Parkinson's disease. Ruottinen, H.M., Rinne, U.K. J. Neurol. (1998) [Pubmed]
  27. Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. Heider, I., Lehmensiek, V., Lenk, T., Müller, T., Storch, A. J. Neural Transm. Suppl. (2004) [Pubmed]
  28. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. Surtees, R., Hyland, K. J. Neurol. Neurosurg. Psychiatr. (1990) [Pubmed]
  29. Method for measuring endogenous 3-O-methyldopa in urine and plasma. Armando, I., Grossman, E., Hoffman, A., Goldstein, D.S. J. Chromatogr. (1991) [Pubmed]
  30. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients. Del Dotto, P., Colzi, A., Pardini, C., Lucetti, C., Dubini, A., Grimaldi, R., Bonuccelli, U. J. Neural Transm. Suppl. (1995) [Pubmed]
WikiGenes - Universities